Galectin Therapeutics Inc.

Following the recent clinical failure of its lead candidate for idiopathic pulmonary fibrosis (IPF), it looks like the end of the road for Galecto Inc. which has slashed its workforce. The US biotec

Galectin Therapeutics Inc. thinks it will be able to initiate its Phase III study of belapectin (GR-MED-02) in non-alcoholic steatohepatitis (NASH) in the first quarter of 2020, having resolved quest

Now that Galectin Therapeutics Inc. has a plan to begin its Phase III study of belapectin (GR-MED-02) in non-alcoholic steatohepatitis (NASH), it has to resolve two fundamental questions – beyond of

Eight biopharmaceutical companies went public in the US during May with mixed results – including mid-month initial public offerings from Applied Therapeutics Inc. , Bicycle Therapeutics Ltd. and